Analyst: US vaccine order secures future cash flow for Bavarian

BARDA has utilized a contract option concerning freeze-dried smallpox vaccines developed by Bavarian, something Sydbank analyst Søren Løntoft Hansen sees as a positive signal for the biotech firm.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali
by marketwire, translated by catherine brett

Bavarian Nordic has secured million-dollar incomes for the next few years, as the US Biomedical Advanced Research and Development Authority (BARDA) has utilized its contracted option on Bavarian’s freeze-dried smallpox vaccine, Jynneos.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading